Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO) (HT173036)

Name: Anti-Human Galectin-9 Reference Antibody (HFB200901, RUO)
Brand: abinScience
SKU: HT173036
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HT173036
Реактивность видов	Human
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG
ID клона	HFB200901
Биологическая активность	Anti-LGALS9 (HFB200901) (10 ug/mL; 1 h) potently inhibits rLGALS9-induced vacuolization in MDCK and DLD-1 KRAS G12C mutant colon carcinoma cells [1]. HFB200901 (20 ug-10 mg; s.c.; once weekly; 8 weeks) reduces pancreatic LGALS9 expression, lowers peripheral and infiltrating Treg levels, increases pancreatic-infiltrating CD4 + T cells, and limits PanIN progression in KC mice [2].
Система экспрессии	Mammalian cells
Цель	Ecalectin, LGALS9, Galectin-9, Gal-9, Tumor antigen HOM-HD-21
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% purity as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	O00182
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4 Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	HFB200901
Фон	Galectin-9 (Gal-9) is a ~39 kDa protein. Binds galactosides. Has high affinity for the Forssman pentasaccharide. Ligand for HAVCR2/TIM3. Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death. Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth. 1. Nagae, M. et al. (2008) Journal of molecular biology 375, 119-35. PMID: 18005988 2. Zhu, C. et al. (2005) Nature immunology 6, 1245-52. PMID: 16286920 3. Bi, S. et al. (2011) Proceedings of the National Academy of Sciences of the United States of America 108, 10650-5. PMID: 21670307 4. Gieseke, F. et al. (2013) European journal of immunology 43, 2741-9. PMID: 23817958 5. Mengshol, JA. et al. (2010) PloS one 5, e9504. PMID: 20209097 6. Dai, SY. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 2974-81. PMID: 16116184 7. Kojima, R. et al. (2014) PloS one 9, e86106. PMID: 24465902 9. Golden-Mason, L. et al. (2013) Journal of virology 87, 4835-45. PMID: 23408620
Ссылки	1. Wiersma VR, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy. 2015;11(8):1373-1388. [HT173036] 2. Quilbe A, et al. A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice. Front Immunol. 2023;14:1267279. Published 2023 Nov 30. [HT173036] 3. Pranjol M Z I, Zinovkin D A, Potapnev M P. The role of galectins in the immune microenvironment in human cancers and potential therapeutic approaches[J]. Frontiers in Immunology, 2024, 15: 1448407. [HT173036] 4. Lu B, et al. LGALS9 blockade augments vaccine-induced immune responses against prostate cancer. J Immunother Cancer. 2026;14(5):e014141. Published 2026 May 8. View More [HT173036]
Примечание	For research use only. Not suitable for clinical or therapeutic use.